BMI in CAR T: Overweight Status Predicts Worse MM Outcomes
Okay, here’s a breakdown of the provided text, focusing on the key information and summarizing it in a clear and concise way.
Main point:
The study found a surprising U-shaped association between BMI and outcomes in patients with multiple myeloma. Being overweight was associated with worse survival and progression-free survival compared to both normal weight and obese patients. This contradicts the common assumption that overweight/obese status offers some protection in cancer.
Key Findings (with data):
* Progression-Free Survival (PFS):
* Overweight: 28.8%
* Normal Weight: 51.9%
* Obese: 62.6%
* (P < .001 - statistically notable difference)
* Overall Survival (OS):
* Overweight: 61.4%
* Normal Weight: 82.9%
* Obese: 84.2%
* (P = .006 - statistically significant difference)
* Complete Response Rate:
* Overweight: 36.4%
* Normal Weight: 42.9%
* Obese: 56.1%
* (P = .185 – not statistically significant)
* Hazard Ratios (HR): (Compared to normal weight/obesity)
* PFS (Multivariate Adjusted): Overweight HR = 1.69 (95% CI, 1.03-2.77; P = .038) – Significantly higher risk of progression.
* OS (Multivariate adjusted): Overweight HR = 2.33 (95% CI, 1.08-5.03; P =.031) – Significantly higher risk of death.
Authors’ Interpretation:
The authors believe that overweight status doesn’t provide the same protective benefits seen in normal weight or obese patients with multiple myeloma,which may explain the poorer outcomes observed in the overweight group. The study supports their original hypothesis.
In essence, this research challenges conventional wisdom about the relationship between BMI and cancer outcomes, specifically in the context of multiple myeloma.